Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combining a TLR9 Agonist With Broadly Neutralizing Antibodies for Reservoir Reduction and Immunological Control of HIV Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial.

NCT03837756 is registered in ClinicalTrials.gov with University of Aarhus as lead sponsor.

NCT NCT03837756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03837756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combining a TLR9 Agonist With Broadly Neutralizing Antibodies for Reservoir Reduction and Immunological Control of HIV Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial.
Lead sponsor
University of Aarhus
Phase
Phase 2
Overall status
Completed
Start date
May 6, 2019
Completion date
May 1, 2023
Enrollment
47 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection